The effect of activation of peroxisome proliferator-activated receptor gamma (PPARγ) on human monocyte function: PPARγ ligands do not inhibit tumor necrosis factor-α release in human monocytic cell line THP-1

Cell Biology and Toxicology

Volumn 16, Issue 2, 2000, Pages 131-135

  Naitoh, Takeshi ^a   Kitahara, M ^a   Tsuruzoe, N ^a  

^a NISSAN CHEMICAL INDUSTRIES LTD   (Japan)

Author keywords

Cell viability; Monocyte; PPAR ; Thiazolidinedione; TNF

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DELTA12 PROSTAGLANDIN J2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHORBOL ESTER; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; HUMAN; HUMAN CELL; LIGAND BINDING; MONOCYTE; PRIORITY JOURNAL; RECEPTOR BINDING;

ANTINEOPLASTIC AGENTS; CARCINOGENS; CELL SURVIVAL; CELLS, CULTURED; CHROMANS; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; MONOCYTES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TETRADECANOYLPHORBOL ACETATE; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033938477     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007694110835     Document Type: Article

References (17)

1. 2 is a ligand for the adipocyte determination factor PPARgamma. Cell. 1995;83;803-12.
2. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, poly-unsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA. 1997;94:4312-7.
3. Franzese O, Bonmassar E, Barcucci A, D'onofrion C. Functional antagonism between OL-2 and PGA1 or PGJ2 in the control of proliferation of human cord blood-derived mono-nuclear cells. Int J Immunopharmacol. 1996;18:609-22.
4. Fujiwara T, Ohsawa T, Takahashi, et al. Troglitazone, a new antidiabetic agent possessing radical scavenging ability, improved decreased skin blood flow in diabetic rats. Life Sci. 1998;63:2039-47.
5. Inoue I, Katayama S, Takahashi K, et al. Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun. 1997;235:113-6.
6. Jiang C, Ting A, Seed B. PPARgamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998; 391:82-6.
7. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology. 1992;130:43-52.
8. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Wilsom TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma). J Biol Chem. 1995; 270:12953-6.
9. Lehmann JM, Lenahard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997;272: 3406-10.
10. Lin R, Ruuska E, Shaw NS, Dong D, Noy N Ligand selectivity of the peroxisome proliferator-activated receptor alpha. Biochemistry. 1999;38:185-90.
11. Murakami K, Tobe K, Ide T et al. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma. Effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes. 1998;47:1841-7.
12. Peraldi P, Spiegelman B. TNF-alpha and insulin resistance: summary and future prospects. Mol Cell Biochem. 1998; 182:169-75.
13. Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clin Invest. 1997;100:1863-9.
14. Reginato MJ, Bailey ST, Krwakow SL et al. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. J Biol Chem. 1998;273:32679-84.
15. Ricote M, Li AC, Wilson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor gamma is a negative regulator of macrophage activation. Nature. 1998; 391:79-82.
16. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45: 1661-9.
17. Szalkowski D, White-Carrington S, Berger J, Zhang B. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology. 1995;136:1474-81.